Your cart
There are no more items in your cart
1 film-coated tablet contains:
Active substance:
Hesperidin + Diosmin (Purified micronized flavonoid fraction [90% diosmin (900 mg), 10% flavonoids in terms of hesperidin (100 mg)]) 1000.0 mg.
Excipients:
microcrystalline cellulose (Vivapur 101) 157.0 mg, povidone (Plasdon K-25) 62.0 mg, sodium carboxymethyl starch type A (Explotab) 26.8 mg, colloidal silicon dioxide (colloidal silicon dioxide anhydrous) (Aerosil 200 Pharma) 6 .2 mg, magnesium stearate (Ligamed MF-2-V) 8.0 mg.
Film shell Opadry II 85F240141 pink: polyvinyl alcohol - partially hydrolyzed (E1203) 15.12 mg, macrogol-3350 (Macrogol / PEG 3350 (E1521)) 7.64 mg, titanium dioxide (E171) 8.61 mg, talc (E553B) ) 5.59 mg, iron dye yellow oxide (E172) 0.48 mg, iron dye red oxide (E172) 0.36 mg.
Pharmacotherapeutic group
venotonic and venoprotective agent
Troxactiv is a purified micronized flavonoid fraction consisting of diosmin and other flavonoids in terms of hesperidin. This combination has venotonic and angioprotective properties. Reduces vein extensibility and venous stasis, in microcirculation - reduces capillary permeability and increases their resistance, improves venous hemodynamics.
Troxactiv affects the following venous plethysmographic parameters: venous capacity, venous distensibility, venous emptying time. The optimal effect is achieved when taking 1000 mg per day. Troxactiv increases venous tone by reducing the time of venous emptying. In patients with signs of a pronounced microcirculation disorder, an increase in capillary resistance is noted.
The therapeutic efficacy of Troxactiv has been proven in relation to venous hemodynamic parameters in the treatment of chronic diseases of the veins of the lower extremities, as well as in the treatment of hemorrhoids.
The main excretion of the drug occurs with feces. With urine, on average, about 14% of the amount of the drug taken is excreted. The half-life is 11 hours.
The drug undergoes active metabolism, as evidenced by the presence of phenolic acids in the urine.
Indications
Troxactiv is indicated for the treatment of symptoms of chronic venous disease (elimination and relief of symptoms).
Therapy of symptoms of venous-lymphatic insufficiency:
- feeling of heaviness and fullness in the legs;
- pain;
- "fatigue" of the legs;
- convulsions of the lower extremities.
Therapy of manifestations of venous-lymphatic insufficiency:
- swelling of the lower extremities;
- trophic changes in the skin and subcutaneous tissue;
- venous trophic ulcers.
Symptomatic therapy of acute and chronic hemorrhoids.
Contraindications
Hypersensitivity to the active or excipients that make up the drug.
Breastfeeding period (experience is limited).
Age up to 18 years (no experience of use).
Use during pregnancy and during breastfeeding
Pregnancy
Animal experiments have not revealed teratogenic effects. To date, there have been no reports of adverse effects when using the drug in pregnant women.
breastfeeding period
Due to the lack of data on the excretion of the drug in breast milk, lactating women are not recommended to take the drug.
Impact on reproductive function
Reproductive toxicity studies have shown no effect on reproductive function in rats of either sex.
Dosage and administration
inside.
The recommended dose for venous-lymphatic insufficiency is 1 tablet per day, preferably in the morning, during a meal.
Tablets should be swallowed whole with water.
The line on the tablet is intended solely for division in order to facilitate swallowing.
The duration of the course of treatment can be several months (up to 12 months).
In case of recurrence of symptoms, on the recommendation of a doctor, the course of treatment can be repeated.
The recommended dose for acute hemorrhoids is 3 tablets per day: 1 tablet in the morning, afternoon and evening for 4 days, then 2 tablets per day: 1 tablet in the morning and evening for the next 3 days.
The recommended dose for chronic hemorrhoids is 1 tablet per day with meals.
Side effects
Side effects observed during clinical studies were of mild severity.
The frequency of side effects is classified in accordance with the recommendations of the World Health Organization: very often (> 1/10); often (>1/100, <1/10); infrequently (> 1/1000, <1/100); rarely (>1/10000, <1/1000); very rarely (including isolated cases) (<1/10000), unspecified frequency (frequency cannot be calculated from the available data).
Gastrointestinal disorders: often - nausea, vomiting, diarrhea, dyspepsia; infrequently - colitis; unspecified frequency - abdominal pain.
Nervous system disorders: rarely - headache, general malaise, dizziness.
Skin and subcutaneous tissue disorders: rarely - skin rash, pruritus, urticaria; unspecified frequency - isolated swelling of the face, lips, eyelids; in exceptional cases - angioedema (Quincke's edema).
If you experience any side effects listed in the instructions, or if they get worse, or if you notice any other side effects not listed in the instructions, tell your doctor.
Overdose
Cases of overdose are not described.
In case of an overdose of the drug, seek medical attention immediately.
drug interaction
Clinical studies on the interaction of the drug Troxactiv with other drugs have not been conducted. To date, no cases of drug interactions have been reported.
Special conditions
- Before you start taking the drug Troxactiv, it is recommended to consult with your doctor.
- In case of exacerbation of hemorrhoids, the appointment of Troxactiv does not replace the specific treatment of other anal disorders. The duration of treatment should not exceed the periods specified in the section "Method of application and doses". In the event that the symptoms do not disappear after the recommended course of therapy, you should be examined by a proctologist who will select further therapy.
- In the presence of venous circulation disorders, the maximum effect of treatment is ensured by a combination of therapy with a healthy (balanced) lifestyle: it is desirable to avoid prolonged exposure to the sun, prolonged stay on the legs, and it is also recommended to reduce excess body weight. Hiking and, in some cases, wearing special stockings improves blood circulation. Seek immediate medical attention if your condition worsens or does not improve during treatment.
Influence on the ability to drive vehicles, mechanisms
Clinical studies on the effect of the drug Troxactiv on the ability to drive a car and perform work that require a high rate of mental and physical reactions have not been conducted. However, based on the available safety data, it can be concluded that Troxactiv has no effect (no significant effect) on these processes.
Active substance:
Hesperidin + Diosmin (Purified micronized flavonoid fraction [90% diosmin (900 mg), 10% flavonoids in terms of hesperidin (100 mg)]) 1000.0 mg.
Excipients:
microcrystalline cellulose (Vivapur 101) 157.0 mg, povidone (Plasdon K-25) 62.0 mg, sodium carboxymethyl starch type A (Explotab) 26.8 mg, colloidal silicon dioxide (colloidal silicon dioxide anhydrous) (Aerosil 200 Pharma) 6 .2 mg, magnesium stearate (Ligamed MF-2-V) 8.0 mg.
Film shell Opadry II 85F240141 pink: polyvinyl alcohol - partially hydrolyzed (E1203) 15.12 mg, macrogol-3350 (Macrogol / PEG 3350 (E1521)) 7.64 mg, titanium dioxide (E171) 8.61 mg, talc (E553B) ) 5.59 mg, iron dye yellow oxide (E172) 0.48 mg, iron dye red oxide (E172) 0.36 mg.
Pharmacotherapeutic group
venotonic and venoprotective agent
Troxactiv is a purified micronized flavonoid fraction consisting of diosmin and other flavonoids in terms of hesperidin. This combination has venotonic and angioprotective properties. Reduces vein extensibility and venous stasis, in microcirculation - reduces capillary permeability and increases their resistance, improves venous hemodynamics.
Troxactiv affects the following venous plethysmographic parameters: venous capacity, venous distensibility, venous emptying time. The optimal effect is achieved when taking 1000 mg per day. Troxactiv increases venous tone by reducing the time of venous emptying. In patients with signs of a pronounced microcirculation disorder, an increase in capillary resistance is noted.
The therapeutic efficacy of Troxactiv has been proven in relation to venous hemodynamic parameters in the treatment of chronic diseases of the veins of the lower extremities, as well as in the treatment of hemorrhoids.
The main excretion of the drug occurs with feces. With urine, on average, about 14% of the amount of the drug taken is excreted. The half-life is 11 hours.
The drug undergoes active metabolism, as evidenced by the presence of phenolic acids in the urine.
Indications
Troxactiv is indicated for the treatment of symptoms of chronic venous disease (elimination and relief of symptoms).
Therapy of symptoms of venous-lymphatic insufficiency:
- feeling of heaviness and fullness in the legs;
- pain;
- "fatigue" of the legs;
- convulsions of the lower extremities.
Therapy of manifestations of venous-lymphatic insufficiency:
- swelling of the lower extremities;
- trophic changes in the skin and subcutaneous tissue;
- venous trophic ulcers.
Symptomatic therapy of acute and chronic hemorrhoids.
Contraindications
Hypersensitivity to the active or excipients that make up the drug.
Breastfeeding period (experience is limited).
Age up to 18 years (no experience of use).
Use during pregnancy and during breastfeeding
Pregnancy
Animal experiments have not revealed teratogenic effects. To date, there have been no reports of adverse effects when using the drug in pregnant women.
breastfeeding period
Due to the lack of data on the excretion of the drug in breast milk, lactating women are not recommended to take the drug.
Impact on reproductive function
Reproductive toxicity studies have shown no effect on reproductive function in rats of either sex.
Dosage and administration
inside.
The recommended dose for venous-lymphatic insufficiency is 1 tablet per day, preferably in the morning, during a meal.
Tablets should be swallowed whole with water.
The line on the tablet is intended solely for division in order to facilitate swallowing.
The duration of the course of treatment can be several months (up to 12 months).
In case of recurrence of symptoms, on the recommendation of a doctor, the course of treatment can be repeated.
The recommended dose for acute hemorrhoids is 3 tablets per day: 1 tablet in the morning, afternoon and evening for 4 days, then 2 tablets per day: 1 tablet in the morning and evening for the next 3 days.
The recommended dose for chronic hemorrhoids is 1 tablet per day with meals.
Side effects
Side effects observed during clinical studies were of mild severity.
The frequency of side effects is classified in accordance with the recommendations of the World Health Organization: very often (> 1/10); often (>1/100, <1/10); infrequently (> 1/1000, <1/100); rarely (>1/10000, <1/1000); very rarely (including isolated cases) (<1/10000), unspecified frequency (frequency cannot be calculated from the available data).
Gastrointestinal disorders: often - nausea, vomiting, diarrhea, dyspepsia; infrequently - colitis; unspecified frequency - abdominal pain.
Nervous system disorders: rarely - headache, general malaise, dizziness.
Skin and subcutaneous tissue disorders: rarely - skin rash, pruritus, urticaria; unspecified frequency - isolated swelling of the face, lips, eyelids; in exceptional cases - angioedema (Quincke's edema).
If you experience any side effects listed in the instructions, or if they get worse, or if you notice any other side effects not listed in the instructions, tell your doctor.
Overdose
Cases of overdose are not described.
In case of an overdose of the drug, seek medical attention immediately.
drug interaction
Clinical studies on the interaction of the drug Troxactiv with other drugs have not been conducted. To date, no cases of drug interactions have been reported.
Special conditions
- Before you start taking the drug Troxactiv, it is recommended to consult with your doctor.
- In case of exacerbation of hemorrhoids, the appointment of Troxactiv does not replace the specific treatment of other anal disorders. The duration of treatment should not exceed the periods specified in the section "Method of application and doses". In the event that the symptoms do not disappear after the recommended course of therapy, you should be examined by a proctologist who will select further therapy.
- In the presence of venous circulation disorders, the maximum effect of treatment is ensured by a combination of therapy with a healthy (balanced) lifestyle: it is desirable to avoid prolonged exposure to the sun, prolonged stay on the legs, and it is also recommended to reduce excess body weight. Hiking and, in some cases, wearing special stockings improves blood circulation. Seek immediate medical attention if your condition worsens or does not improve during treatment.
Influence on the ability to drive vehicles, mechanisms
Clinical studies on the effect of the drug Troxactiv on the ability to drive a car and perform work that require a high rate of mental and physical reactions have not been conducted. However, based on the available safety data, it can be concluded that Troxactiv has no effect (no significant effect) on these processes.
5900004074791
Tap to zoom
